France Herceptin Market Size, Share, and COVID-19 Impact Analysis, By Product (Biosimilar, Biologic), By Application (Breast Cancer, Stomach/Gastric Cancer), and France Herceptin Market Insights, Industry Trend, Forecasts to 2035

France Herceptin Market Insights Forecasts to 2035 

• The France Herceptin Market Size was Estimated at USD 118.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 3.10% from 2025 to 2035
• The France Herceptin Market Size is Expected to Reach USD 165.8 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The France Herceptin Market Size is anticipated to Reach USD 165.8 Million by 2035, Growing at a CAGR of 3.10% from 2025 to 2035. The growing prevalence of HER2-positive breast cancer and growing awareness of targeted cancer treatments nationally are the main factors propelling the market.

Market Overview 

The France Herceptin Market Size is the market for Herceptin (trastuzumab), a monoclonal antibody that treats specified cancers, including HER2-positive breast cancer and gastric cancer. This industry concerns sales of Herceptin, Herceptin biosimilars, and related products. The market is being pulled mainly by two factors: far-reaching awareness of targeted cancer treatment and rising incidences of HER2-positive breast cancer. Herceptin (trastuzumab) is a well-known biologic with established efficacy and history, equivocally seen as an element of personalized medicine, plus having helped tremendously in the development of personalized medicine at large. Demand is also supported by the diagnostic improvements and an aging population group, and a budding healthcare infrastructure. However, being the time of patent expiration for Herceptin, pressure is being put on the market by biosimilar brands to capture Herceptin sales. Despite being under this pressure, the market remains strong due to ongoing research efforts, and a surge in acceptance of the use of Herceptin for gastric cancer promotes market relevance through active development of current assets and keeps this market alive.

Report Coverage

This research report categorizes the market size for the France Herceptin market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France Herceptin market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France Herceptin market. 

Driving Factors

One of the primary drivers of the France Herceptin market is the increasing incidence of HER2+ breast cancer, a more aggressive and unresponsive subtype of conventional chemotherapy. Targeted therapies via Herceptin are an essential part of the treatment for HER2+ breast cancer. While there have been increased awareness campaigns around cancer and screening programs in place, it is helpful that with accurate diagnosis of HER2, earlier diagnosis is also possible, with the demand for a proper response to HER2+ breast cancer. Advances in molecular diagnostics are now assisting clinicians in identifying their patients who can benefit from Herceptin therapy and integrating Herceptin into standard oncology care.

Restraining Factors

The France market for Herceptin has challenges from the biogeneric competition, formulary considerations, and the new possibility of price negotiations with Medicare. Other factors influencing the market include uncertainty over the safety and efficacy of biosimilars and access to care differences for some regions.

Market Segmentation

The France Herceptin market share is classified into product and application.

• The biosimilar segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France Herceptin market is segmented by product into biosimilar and biologic. Among these, the biosimilar segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period. Increased demand for affordable oncology treatments, patent expirations in significant markets, and the growing acceptance of biosimilars by payers and clinicians are the main causes of the biosimilar uptake boom.

• The breast cancer segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France Herceptin market is segmented by application into breast cancer, stomach/gastric cancer. Among these, the breast cancer segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. Herceptin's well-established position as the gold standard for treating HER2-positive breast cancer in early-stage, adjuvant, and metastatic settings is what drives this stronghold.  Its continued leadership is a result of a wealth of clinical data, the support of guidelines, and oncologists' longstanding familiarity with it.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France Herceptin market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

List of Key Companies

• Roche Holding AG (Genentech)
• Shanghai Henlius Biotech, Inc.
• Amgen Inc.
• Biocon Limited
• Pfizer Inc.
• Celltrion Healthcare Co., Ltd.
• Mylan N.V. (Viatris)
• Samsung Bioepis Co., Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France Herceptin Market based on the below-mentioned segments:

France Herceptin Market, By Product                                                

• Biosimilar
• Biologic

France Herceptin Market, By Application                                                         

• Breast Cancer
• Stomach/Gastric Cancer